Literature DB >> 1147

L-[alphaS, 5S]-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (NSC-163501): a new amino acid antibiotic with the properties of an antagonist of L-glutamine.

H N Jayaram, D A Cooney, J A Ryan, G Neil, R L Dion, V H Bono.   

Abstract

L-[alphaS,5S]-alpha-amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid (NSC-163501), an antibiotic elaborated by Streptomyces sviceus, has been shown to be a powerful inhibitor of many mammalian and bacterial reactions involving the transfer of nitrogen from the gamma-carboxamide of L-glutamine. Thus, the utilization of L-glutamine for the synthesis of carbamyl phosphate, L-asparagine, guanosine-5'-monophosphate, cytidine-5'-triphosphate, N-formylglycinamidine ribonucleotide, NAD, glucosamine-6-phosphate, and anthranilic acid is strongly or totally inhibited by a concentration of NSC-163501 of 1 X 10(-3) M. L-Glutamate synthetase of Escherichia coli is only modestly inhibited and 5-phosphoribosylamine synthesis in fetal rat liver is comparatively refractory to inhibition. NSC-163501 treatment of L1210 cells growing in a low L-glutamine culture medium produced arrest in G or early S phase. Of the amino acids tested, only L-glutamine antagonized such growth inhibition.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1147

Source DB:  PubMed          Journal:  Cancer Chemother Rep        ISSN: 0069-0112


  10 in total

1.  Oncolytic activity and mechanism of action of a novel L-cysteine derivative, L-cysteine, ethyl ester, S-(N-methylcarbamate) monohydrochloride.

Authors:  H N Jayaram; M S Lui; J Plowman; K Pillwein; M A Reardon; W L Elliott; G Weber
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Biochemical mechanisms for the scheduled synergism of (alpha S, 5S)-2 amino-3-chloro-4,5-dihydro-5-isoxazoleacetic acid and 5-fluorouracil in P388 leukemia.

Authors:  B Ardalan; B Chandrasekaran; H J Hrishikeshavan
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

3.  Phase I evaluation of AT-125 single dose every three weeks.

Authors:  S Taylor; R J Belt; U Joseph; C D Haas; B Hoogstraten
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

Review 4.  Targeting mitochondrial metabolism for precision medicine in cancer.

Authors:  Lourdes Sainero-Alcolado; Judit Liaño-Pons; María Victoria Ruiz-Pérez; Marie Arsenian-Henriksson
Journal:  Cell Death Differ       Date:  2022-07-13       Impact factor: 12.067

Review 5.  New agents in the treatment of primary brain tumors.

Authors:  S A Taylor
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

6.  Intracerebral chemotherapy in the 9L rat brain tumor model.

Authors:  B F Kimler; C Liu; R G Evans; R A Morantz
Journal:  J Neurooncol       Date:  1992-11       Impact factor: 4.130

7.  Phase II trial of acivicin in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group Study.

Authors:  W P McGuire; J A Blessing; P J DiSaia; H J Buchsbaum
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

8.  An in vivo large-scale chemical screening platform using Drosophila for anti-cancer drug discovery.

Authors:  Lee F Willoughby; Tanja Schlosser; Samuel A Manning; John P Parisot; Ian P Street; Helena E Richardson; Patrick O Humbert; Anthony M Brumby
Journal:  Dis Model Mech       Date:  2012-09-20       Impact factor: 5.758

9.  Cell cycle phase perturbations by 6-diazo-5-oxo-L-norleucine and acivicin in normal and neoplastic human cell lines.

Authors:  K R Huber; E P Mayer; D F Mitchell; J Roberts
Journal:  Br J Cancer       Date:  1987-06       Impact factor: 7.640

10.  Target discovery of acivicin in cancer cells elucidates its mechanism of growth inhibition†Electronic supplementary information (ESI) available: Synthesis, cloning, protein expression, purification and biochemical assays. See DOI: 10.1039/c4sc02339k.

Authors:  Johannes Kreuzer; Nina C Bach; Daniel Forler; Stephan A Sieber
Journal:  Chem Sci       Date:  2014-09-26       Impact factor: 9.825

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.